*Autobio is devoted to enhancing the quality of our products and services. Please refer to our product manuals for detailed specifications and parameters.

CA 19-9 and CA 50

Although discovered 30 years ago, CA 19-9 remains the gold standard serum marker for patients with pancreatic cancer.[1] Follow-up using CA 19-9 and CA 50 is a simple and sensitive way of monitoring the postoperative course of patients with pancreatic cancer, and may give a lead time of several months for a recurrence compared to conventional methods.

CA242 and CA19-9

CA242 and CA19-9 have better performance in the diagnosis of pancreatic cancer than CEA. Furthermore, parallel combination pattern of CA19-9+CA242 could be considered of better diagnostic value for pancreatic cancer patients.[4]

CA 19-9 and CA 125

CA50 is a glycolipid antigen that plays an important role in cell growth and differentiation. Subgroup analyses indicated that CA50 was the only tumor biomarker that was significantly correlated with long-term survival in CEA-normal CRC patients.[2]

CA125

Increased levels of the CA 19-9 and CA 125 markers in patients with pancreatic pathological abnormalities usually indicates a malignant nature of the lesion.[5]

CEA

Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Furthermore, high levels of serum CEA are significantly related to poor prognosis of patients with pancreatic cancer. Thus, the measurement of serum CEA, as a vital supplementary to CA19-9, is inexpensive, convenient, and necessary for monitoring this disease.[6]